<DOC>
	<DOCNO>NCT00414648</DOCNO>
	<brief_summary>Lymphangioleiomyomatosis ( LAM ) rare lung disease cause genetic mutation . It result uncontrolled growth proliferation unusual type smooth muscle cell . These cell invade lung tissue , include airway , blood vessel , lymph vessel , restrict flow air , blood , lymph , respectively . Respiratory failure , lung collapse ( pneumothorax ) , pleural effusion ( chylothorax ) hallmarks disease . This study evaluate safety effectiveness sirolimus , immunosuppressive medication , stabilize improve lung function people LAM .</brief_summary>
	<brief_title>Efficacy Safety Sirolimus Treating Lymphangioleiomyomatosis ( LAM )</brief_title>
	<detailed_description>LAM uncommon , progressive , cystic lung disease predominantly affect young woman . It believe caused defect within cellular pathway regulate nutrient uptake , cell size , cell migration , cell proliferation . The disease cause mutation tuberous sclerosis complex ( TSC ) gene . Individuals LAM often experience pneumothorax chylothorax , well progressive loss lung function . LAM frequently fatal exist therapy disease proven effective . Lung transplantation consider last option , alternative treatment need . Sirolimus immunosuppressive drug often used people kidney transplant . It directly affect genetic pathway cause LAM . This study evaluate safety effectiveness sirolimus stabilize improve lung function people LAM . Individuals interested participate 2-year , double-blind study first report study sit pulmonary function test determine eligibility participation . Participants deem eligible randomly assign receive either sirolimus placebo 1 year . Sirolimus placebo administer 2 tablet dos ( 2 mg sirolimus ) duration study . Study visit occur baseline , Week 3 , every 3 month 12 month , Months 18 24 . Study visit include physical exam , questionnaire , pregnancy test , blood urine collection , functional lung test . A 6-minute walk test occur study visit ; chest x-ray take baseline Month 24 ; volumetric compute tomography scan occur baseline , Month 12 , Month 24 . Adverse event , medication side effect , lung function assess visit .</detailed_description>
	<mesh_term>Lymphangioleiomyomatosis</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Age 18 old Diagnosis LAM determine biopsy chest CT scan ; chest CT scan set tuberous sclerosis , angiomyomata chylous pleural effusion ; chest CT scan VEGFD level least 800 pg/ml Forced expiratory volume one second ( FEV1 ) 70 % le predicted value administration bronchodilator Known allergy sirolimus History heart attack , angina , stroke due clogging , narrow , harden artery blood vessel Significant hematologic hepatic abnormality ( transaminase level great three time upper limit normal , HCT le 30 % , platelets less 80,000/cubic mm , adjust absolute neutrophil count le 1,000/cubic mm , total white blood cell count le 3,000/cubic mm ) Intercurrent infection time treatment sirolimus begin Any surgery involve entry body cavity require three suture within 8 week initiation study drug Use investigational drug within 30 day prior random assignment Uncontrolled hyperlipidemia Previous lung transplant currently lung transplant list Unable attend schedule study visit Unable perform pulmonary function test Creatinine level great 2.5 mg/dl Chylous ascites severe enough affect diaphragmatic function Pleural effusion severe enough affect pulmonary function , determine study physician History acute pneumothorax within 2 month prior study entry History malignancy within 2 year prior study entry ( except squamous basal cell skin cancer ) Use estrogen contain medication within thirty day prior randomization Unable unwilling use adequate contraception Pregnant , breastfeeding , plan become pregnant within next 2 year</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Lymphangiomyomatosis</keyword>
	<keyword>Lung Disease</keyword>
</DOC>